Loading clinical trials...

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection | Clinical Trials | Clareo Health

RECRUITINGNA

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

NCT05879159•M.D. Anderson Cancer Center

View on ClinicalTrials.gov

Summary

To learn if an accelerated recovery program can shorten the length of hospital stay in patients having minimally invasive liver surgery.

Detailed Description

Primary Objectives: Our study will investigate the feasibility of an accelerated recovery program to minimize length of stay (LOS) and facilitate outpatient surgery for patients undergoing minimally invasive, lower complexity (Kawaguchi-Gayet grade I) liver resection. This program (ARAMIS Hep) will combine minimally invasive surgical (MIS) approaches (robotic OR laparoscopic), enhanced recovery after surgery (ERAS) protocols, and Telehealth to liberalize discharge criteria in a safe manner. Secondary Objectives: In addition to demonstrating a reduction in LOS, our study will also provide preliminary data to aid in the broader implementation of this approach. Specifically, we will gain insight into the patient experience, measure patient-reported outcomes on recovery trajectories, and understand barriers to integrating a novel pathway into existing institutional frameworks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Tumor amenable to MIS Kawaguchi-Gayet grade I hepatectomy (see figure 1 below)
•No evidence of cirrhosis (based on imaging, evidence of portal hypertension, clinical features, or laboratory results)
•No significant cardiopulmonary disease that would prevent patients from undergoing MIS resection
•Ability to stay within 50 miles of medical center for immediate postop period
•Age of 18 years or above - because no adverse event data are currently available on enhanced recovery and early discharge after hepatic resection for patients \<18 years of age, children are excluded from this study
•Ability to understand and the willingness to sign a written informed consent document
•Non-English-speaking patients are eligible for participation

Exclusion Criteria

•Patients who will be excluded include those with:
•Tumors NOT amenable to MIS Kawaguchi-Gayet grade I hepatectomy
•Tumors not amenable to MIS or Robotic-assisted surgical resection
•Evidence of Cirrhosis on imaging, clinically, or lab testing
•Inability to stay within 50 miles of the Cancer Center in the immediate post-operative period
•Age below 18 years
•Inability to consent for trial/protocol
•Patients who are pregnant

Locations (1)

M D Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

October 5, 2023

Primary Completion Date

February 1, 2027

Completion Date

February 1, 2027

Last Updated

February 3, 2026

Enrollment

ESTIMATED participants

Conditions

Liver

Interventions

Questionnaires

BEHAVIORAL

Contacts

Hop Tran Cao, MD

CONTACT

(713) 745-4670 hstran@mdanderson.org

Evaluation of Resection Techniques for Pancreatic Tumors

NCT05128890

SurgeryLiver Tumor+1 more

View study

RECRUITING

Early Detection of Liver Cancer by QUS

NCT06345508

Hepatocellular CarcinomaLiver Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection

Inclusion Criteria

Exclusion Criteria

Evaluation of Resection Techniques for Pancreatic Tumors

Early Detection of Liver Cancer by QUS

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry

Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)